Skip to main content
. 2015 Jun 1;20(10):1337–1345. doi: 10.1111/tmi.12544

Figure 2.

Figure 2

Comparison of mean cost‐by‐cost category between rifampicin mono‐resistant/MDR‐TB cases and MDR‐TB with second‐line resistance (including XDR‐TB). RIF‐mono, rifampicin mono‐resistance; MDR‐TB, multidrug‐resistant TB; PHC, primary health care; USD, US dollars.